Siren Biotechnology’s Post

I am glad to share the news that my research paper "Development and Bioactivity Assessment of a Recombinant Pseudomonas aeruginosa Azurin-BR2 Peptide Fusion Protein: A Novel Approach to Cancer Immunotherapy" has been published in the "Journal of Biological Regulators and Homeostatic Agents". #JournalofBiologicalRegulatorsandHomeostaticAgents #Researchpaper #Molecularbiology #Recombinantdnatechnology

Single Cell Proteomics at Scale Getting really clear on the proteins you are interested in allows you to crank up the throughput to analyze more cells than previously thought to be feasible. Benjamin Orsburn used the Evosep One to show this with cancer cells, analyzing up to 3,500 cells per day! When it comes to Single Cell Proteomics, biological insight is about more than just maximizing protein IDs. https://lnkd.in/edJ8qbbu #lcms #singlecell #proteomics

The Next Wave of ADCs Could Treat Evasive Solid Tumor 👨🔬 Advances in antibody-drug conjugates, including novel payloads and new targets, will be featured at the American Association for Cancer Research's annual conference, taking place this week in San Diego, where companies, including Elevation Oncology and Tubulis, will present new data from their respective programs. 👩🔬 Take a look at the full article here - BioSpace - https://lnkd.in/ewwP3NUn #biotech #biotechnology #biology #technology

Glad to see our latest review paper "Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions" accepted for publication in Biomolecules MDPI journal. https://lnkd.in/d8SYyRv6 In this work, together with Denys Bondar , who spent year(s) of his PhD journey on this topic☝️, we reviewed the properties, characteristics, and challenges of PARP inhibitors, discussing their development from first-generation to third-generation compounds, more #green and #sustainable routes for synthesis of new anti-cancer agents, their mechanisms of therapeutic action, and potential for targeting additional biological targets beyond the catalytic active site of PARP proteins.

New biomarker helps determine the optimal treatment for colon cancer. A study published July 25th, 2024 in Cell Reports Medicine identifies and validates a 10-gene biomarker that potentially predicts whether a stage II or III colon cancer patient will benefit from adjuvant chemotherapy. Read :  https://lnkd.in/ey7_nHTm Xi (Steven) Chen University of Miami Miller School of Medicine #sciencesdelavie #biotechnology #biotechnology #innovation #innovations #research #sciences #medicaments #research #drugresearch #laboratories #labs #chemistry #chemistry #biology #biologie #biopharma #rna #rnatherapeutics #arn #revolution #happy

This year, more than 20,000 cases of acute myeloid leukemia are estimated to be diagnosed. At Purdue University, a team of researchers have developed a compound for patients who have developed resistance to traditional treatment. Herman Sintim is a researcher in Purdue University College of Science, the Purdue Institute for Cancer Research, and Purdue Institute for Drug Discovery. He and other scientists at Purdue, the Indiana University School of Medicine, and KinaRx, a biotechnology company, have collaborated to develop and test the compound, named HSN748. Full story via Technology Networks: https://bit.ly/4cgOrgH   KinaRx has licensed the compound from the Purdue Innovates Office of Technology Commercialization. #Purdue #PurdueInnovates #Leukemia #Cancer #Treatment

Simple, Modular Enantiocontrolled Azetidine Library Synthesis via Strain Release Functionalization of 1-Azabicyclobutanes The synthetic methods developed enable parallel synthesis of stereodefined azetidines that would be otherwise laborious to produce. Given the privileged nature of these structures, a set of stereoprobes for use in activity-based protein profiling was prepared and evaluated, revealing proteins in human cancer cells with were liganded with clear stereo- and chemoselectivity. https://lnkd.in/gic9YG_n

🔬 Recent studies demonstrate the use of microcarriers for large-scale production of HEK293T cells—a challenging task when working with adherent cells. The research focuses on screening active compounds from Fructus evodiae targeting the FGFR4 receptor, which plays a key role in cancer therapy. By utilizing microcarrier technology, the study shows how drug screening can be more efficient and biomimetic, mimicking in vivo conditions for better results. Learn more about this innovative method and its applications on our website 👉: https://lnkd.in/gu6nj7zk Do you need help with large-scale expansion of HEK293T cells? Reach out to our panel of experts to help you adapt to microcarrier culture: info@smartmcs.com.au #HEK293T #CellCulture #Microcarriers #DrugDiscovery #CancerResearch #Biotech #ScalingScience

My new publication with Riyona Desvy Pratiwi, Sjaikhurrizal El Muttaqien, Siti Irma Rahmawati, Asep Bayu, Sui Ling Janet Tan, Nunik Gustini, Peni Ahmadi, and Masteria Yunovilsa Putra titled: A facile and simple synthesis of a cytotoxic tocotrienol-based nanoemulsion against MCF-7 and A549 cancer cell lines already published on Colloid and Polymer Science. Our research focused on development of tocotrienol-loaded nanoemulsion to improve the bioavailability and stability of Tocotrienol as anticancer agent. You can access our paper through: https://lnkd.in/gzDTGybs

In April, the Heidelberg Pharma AG team attended AACR in San Diego, where we presented promising first efficacy data on our lead clinical #ATAC product candidate, HDP-101, targeting relapsed and refractory multiple myeloma.   Our CMO, Andras Strassz, MD, MBA, spoke to Drug Discovery World´s Megan Thomas about his key takeaways from the conference and our goal of making #Amanitin available as a cancer therapy.   Check out Drug Discovery World's latest issue, linked here: https://lnkd.in/gtSZijU9   #ADCs #ATAC #ACR24 #CancerResearch